Today's Perspective
Kristin Wiisanen PharmD, FAPhA, FCCP, Pharmacy Today editor in chief
FDA’s approval of lenacapavir (Yeztugo—Gilead) this summer marked a potential turning point in the fight against HIV. Administered just twice yearly, this long-acting injectable PrEP therapy demonstrated a 99% reduced risk of acquiring HIV through sexual intercourse. Continued development of emerging medications such as lenacapavir and others could transform HIV prevention by reducing stigma, simplifying adherence, and reaching patients who might otherwise be left behind. Lenacapvir and other PrEP medications come at a high cost, though, and many patients will continue to choose generics, manufacturer programs, or other options to improve accessibility.
This issue of Pharmacy Today explores new developments in HIV prevention and treatment and their effect on patient care. Pharmacists, especially, are central to making this potential impact a reality. Two of the biggest hurdles to effective prevention with PrEP are education and adherence. Pharmacists’ accessibility in community and clinic settings means we are often the first point of contact for patients seeking HIV prevention. In many states, pharmacists can independently prescribe PrEP, administer injectables, and connect patients with assistance programs to overcome cost and other barriers. With lenacapavir now in the toolbox, pharmacists are uniquely positioned to expand PrEP uptake and adherence, particularly among high-risk and underserved populations.
In this issue of Today, you’ll also find updates on other new drug approvals, potential dangers of electrolyte packets for rehydration, and the latest trends in weight loss medication use for teens. You’ll also learn about emerging recommendations for treating neuropathic pain and the role of the pharmacist in penicillin allergy testing, and catch up on your CPE with this month’s article on suicide prevention.
The ability to stop HIV before it starts is within closer reach than ever. For pharmacists, the charge is clear: We must continue to lead, educate, and advocate so that this breakthrough translates into lives saved and healthier communities nationwide. ■